(ICCC)

Reporting relationship: President and CEO, Director
Issuer ticker: ICCC
Reported as of: 27 Jan 2026
Net transaction value: $0
SEC form: 4/A - Amendment
Accepted by SEC: 23 Mar 2026, 09:47:04 UTC
Original report date: 29 Jan 2026
Prior SEC filing: 04 Dec 2025
Next SEC filing: 22 Jun 2026
Source filing: View source filing
Reporting owner signature: /s/ Timothy C. Fiori Attorney-in-Fact

Key filing fact

Boekhorst Paul Francis Olivier Te filed Form 4/A - Amendment for IMMUCELL CORP /DE/ (ICCC) on 23 Mar 2026.

Key facts

This page summarizes Boekhorst Paul Francis Olivier Te's Form 4/A - Amendment filing for IMMUCELL CORP /DE/ (ICCC).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 23 Mar 2026, 09:47.

Change

Previous filing in this sequence was filed on 04 Dec 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4/A - Amendment disclosures.

View source filing

Reporting Owners (1)

CIK 0002095704 Primary reporting owner

te Boekhorst Paul Francis Olivier

Relationship: President and CEO, Director
Address: C/O IMMUCELL CORPORATION, 56 EVERGREEN DRIVE, PORTLAND
Signature: /s/ Timothy C. Fiori Attorney-in-Fact
Signature date: 23 Mar 2026

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

ICCC transaction Derivative

Stock Options (right to buy)

Award

Transaction value
Shares: +109,500
Change %
Price: $0.000000^*
Shares after: 109,500
Date: 27 Jan 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 109,500
Exercise price: $6.26
Footnotes: F1, F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

This amendment amends the previously reported transaction effective on 1/27/2026 to disclose the correct number of shares included in the option award.

Footnote F2

Option grant made to Mr. te Boekhorst in connection with his employment as President and CEO. The option shall be treated as an incentive stock option to the maximum extent permitted by the Internal Revenue Code of 1986, as amended, with the balance treated as nonqualified stock option. One hundred percent of the stock option will vest when the Issuer's net operating income for four consecutive calendar quarters equals or exceeds 300% of the Issuer's audited net operating income for its 2025 fiscal year.